NovoCure Ltd (NASDAQ: NVCR) closed the day trading at $14.90 down -2.10% from the previous closing price of $15.22. In other words, the price has decreased by -$0.32 from its previous closing price. On the day, 1234720 shares were traded.
Ratios:
For a better understanding of NVCR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.56 and its Current Ratio is at 5.78. In the meantime, Its Debt-to-Equity ratio is 1.67 whereas as Long-Term Debt/Eq ratio is at 1.64.
On August 28, 2023, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $85 to $25.
Piper Sandler Upgraded its Neutral to Overweight on August 08, 2023, while the target price for the stock was maintained at $45.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 07 when Shah Pritesh sold 382 shares for $12.65 per share. The transaction valued at 4,832 led to the insider holds 124,511 shares of the business.
Cordova Ashley sold 883 shares of NVCR for $19,265 on Sep 01. The Chief Financial Officer now owns 99,650 shares after completing the transaction at $21.82 per share. On Sep 01, another insider, GROENHUYSEN WILHELMUS CM, who serves as the Chief Operating Officer of the company, sold 294 shares for $21.82 each. As a result, the insider received 6,414 and left with 209,825 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVCR now has a Market Capitalization of 1.60B and an Enterprise Value of 1.28B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.13 while its Price-to-Book (P/B) ratio in mrq is 4.40. Its current Enterprise Value per Revenue stands at 2.52 whereas that against EBITDA is -7.22.
Stock Price History:
Over the past 52 weeks, NVCR has reached a high of $83.60, while it has fallen to a 52-week low of $10.87. The 50-Day Moving Average of the stock is 14.29, while the 200-Day Moving Average is calculated to be 27.20.
Shares Statistics:
Over the past 3-months, NVCR traded about 1.34M shares per day on average, while over the past 10 days, NVCR traded about 1.13M shares per day. A total of 107.08M shares are outstanding, with a floating share count of 96.84M. Insiders hold about 9.57% of the company’s shares, while institutions hold 84.78% stake in the company. Shares short for NVCR as of Jan 31, 2024 were 5.77M with a Short Ratio of 4.32, compared to 6.93M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 5.40% and a Short% of Float of 7.52%.
Earnings Estimates
Current recommendations for the stock of the company come from 7 analysts. On average, analysts expect EPS of -$0.43 for the current quarter, with a high estimate of -$0.36 and a low estimate of -$0.52, while EPS last year was -$0.5. The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.37 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$1.49 and -$1.99 for the fiscal current year, implying an average EPS of -$1.73. EPS for the following year is -$1.84, with 7 analysts recommending between -$1.48 and -$2.38.
Revenue Estimates
5 analysts predict $131.83M in revenue for the current quarter. It ranges from a high estimate of $135M to a low estimate of $129.43M. As of the current estimate, NovoCure Ltd’s year-ago sales were $127.28M, an estimated increase of 3.60% from the year-ago figure.
A total of 7 analysts have provided revenue estimates for NVCR’s current fiscal year. The highest revenue estimate was $546.9M, while the lowest revenue estimate was $531.4M, resulting in an average revenue estimate of $538.93M. In the same quarter a year ago, actual revenue was $509.34M, up 5.80% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $579.17M in the next fiscal year. The high estimate is $596.9M and the low estimate is $567M. The average revenue growth estimate for next year is up 7.50% from the average revenue estimate for this year.
